MDS 2023 | Selecting patients with CMML for alloSCT
Eric Solary, MD, Gustave Roussy Institute, Paris, France, discusses scenarios in which allogeneic stem cell transplantation (alloSCT) is or not useful in patients with chronic myelomonocytic leukemia (CMML). Prof. Solary explains that, although alloSCT is the only curative treatment for CMML currently available, it cannot be recommended to all patients for reasons such as age and presence of comorbidities. Prof. Solary further notes that alloSCT should not be recommended to patients with low-grade forms of CMML. These patients should instead be monitored, and alloSCT may be considered later in the treatment sequence if the disease progresses to a more severe form. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
